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Immunological and epidemiological evidence suggests that
female sex hormones play an important role in the aetiology
and pathophysiology of chronic inflammatory diseases; however,
whether (or when) estrogens are friends or foes in inflammatory/
immune-mediated rheumatic diseases is still a matter of debate [1].
Several significant factors generate confusion and opposite
conclusions might arise from the relatively superficial trans-
lation done from the animal studies to the human condition,
the different effects of oestrogens on their different receptors or
on different target cells, the different oestrogen concen-
trations employed and finally, opposite effects (especially on
cell proliferation) exerted by different peripheral oestrogen
metabolites.
Pregnancy represents a singular condition of physiological
interference on hormonal and immunological behaviour in
females affected by chronic autoimmune diseases.
For example, one paper in this issue discusses molecular and
clinical disease activity markers in RA patients during the third
trimester of pregnancy [2]. Furthermore, a further paper discusses
when and whether autoantibodies might act as predictors of
pregnancy complications [3]. Pregnancy in chronic autoimmune
diseases such as SLE, SSc, RA and others is reviewed.
Management of chronic autoimmune diseases and vasculitis in
pregnancy is often a challenge. This is particularly true in the
patient with organ involvement or organ damage. SLE shows a
broad spectrum of disease manifestations ranging from mild
symptoms to severe conditions that threaten maternal and fetal
health. Similar risks are found in SSc and the different types of
vasculitis. The APS alone or complicating the autoimmune
diseases is characterized by thrombosis and pregnancy morbidity.
Four papers deal with the problems associated with these
conditions and address their management [4–7]. A multidisciplin-
ary approach has been found essential in dealing with these high-
risk pregnancies and achieving a successful outcome.
Improved diagnostic skills in detecting impaired fetal health
have helped to offer early treatment for children at risk though
effective prevention of risk is still far away.
After the introduction of biological agents, the management
of several rheumatic diseases has changed dramatically. As a
consequence of better control of disease activity more patients
consider pregnancy. However, pregnancy experience with regard
to new drugs is in general scanty and leaves both the patient with a
desire for children and the treating physician in a dilemma. Two
papers present the actual knowledge on the interaction of
immunosuppressive drugs and reproduction [8, 9]. Importantly
not only drug treatment during pregnancy and lactation, but also
long-term effects on antenatally exposed offspring are discussed.
Treatment of infertility in patients with autoimmune rheumatic
diseases represents a further condition to be carefully evaluated
and a paper is devoted to this issue [10].
In conclusion, the present issue represents the most up-to-date
knowledge on the topic of pregnancy and autoimmune rheu-
matic diseases and how it is managed by the best experts in the
field.
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